Siegfried Georg Priglinger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Siegfried Georg Priglinger has a total of 368 co-authors. Here are the top co-authors by number of shared publications:
- Jakob Siedlecki
Department of Ophthalmology, LMU University Hospital, Ludwig-Maximilians-University, 80539 Munich, Germany
16 shared publications - Nikolaus Luft
Department of Ophthalmology, University Hospital, LMU Munich, Mathildenstrasse 8, 80336 Munich, Germany
14 shared publications - Benedikt Schworm
Department of Ophthalmology, LMU University Hospital, Ludwig-Maximilians-University, 80539 Munich, Germany
11 shared publications - Stefan Kassumeh
Department of Ophthalmology, University Hospital, LMU Munich, Mathildenstrasse 8, 80336 Munich, Germany
11 shared publications - Claudia Priglinger
Department of Ophthalmology, LMU University Hospital, LMU Munich, Munich, Germany
10 shared publications - Leonie Franziska Keidel
Department of Ophthalmology, LMU University Hospital, LMU Munich, Mathildenstr. 8, 80336 Munich, Germany
10 shared publications
Latest Publications
- Open Access
Impact of Iris Color and Laterality on Lenticule Extraction Time in Keratorefractive Lenticule Extraction (KLEx)
Purpose: This study aims to evaluate the effects of iris color and laterality on keratorefractive lenticule extraction (KLEx) surgery time. Setting: A retrospective analysis was conducted on 656 eyes of 328 patients undergoing small incision lenticule extraction (SMILE). Mean patient age was 32 ± 7 years. Methods: Preoperative parameters, including manifest refraction spherical equivalent (MRSE), refractive cylinder, and corrected distance visual acuity (CDVA), were measured. Iris color was classified as “light” (n = 390) or “dark” (n = 266) by a senior ophthalmologist as the grader. Surgical time was determined from video recordings, defined as the time between opening of the KLEx incision and extraction of the lenticule. The surgery was performed by a single highly experienced, right-handed refractive surgeon. Results: Eyes with light irides showed significantly shorter lenticule extraction times than those with dark irides (75 ± 22 s vs. 90 ± 31 s, p < 0.0001). No statistically significant differences were found between eyes with light and dark irides in terms of postoperative MRSE, refractive cylinder, uncorrected distance visual acuity (UDVA), CDVA, safety and efficacy index, respectively (p > 0.05 for all). Surgical time was significantly shorter in right eyes compared to left eyes (74 ± 25 s vs. 89 ± 27 s, p < 0.0001). When analyzing laterality and iris color, surgery was shortest in right eyes with light irides (68 ± 19 s) and longest in left eyes with dark irides (97 ± 31 s; p < 0.0001). Conclusions: SMILE surgery took significantly less time in patients with light irides and in the right eyes compared to dark irides and the left eyes. These findings suggest that patients’ iris color and laterality in relation to surgeon handedness may influence the ease of surgical lenticule extraction to a comparable extent.
Open AccessImpact of Iris Color and Laterality on Lenticule Extraction Time in Keratorefractive Lenticule Extraction (KLEx)
Purpose: This study aims to evaluate the effects of iris color and laterality on keratorefractive lenticule extraction (KLEx) surgery time. Setting: A retrospective analysis was conducted on 656 eyes of 328 patients undergoing small incision lenticule extraction (SMILE). Mean patient age was 32 ± 7 years. Methods: Preoperative parameters, including manifest refraction spherical equivalent (MRSE), refractive cylinder, and corrected distance visual acuity (CDVA), were measured. Iris color was classified as “light” (n = 390) or “dark” (n = 266) by a senior ophthalmologist as the grader. Surgical time was determined from video recordings, defined as the time between opening of the KLEx incision and extraction of the lenticule. The surgery was performed by a single highly experienced, right-handed refractive surgeon. Results: Eyes with light irides showed significantly shorter lenticule extraction times than those with dark irides (75 ± 22 s vs. 90 ± 31 s, p < 0.0001). No statistically significant differences were found between eyes with light and dark irides in terms of postoperative MRSE, refractive cylinder, uncorrected distance visual acuity (UDVA), CDVA, safety and efficacy index, respectively (p > 0.05 for all). Surgical time was significantly shorter in right eyes compared to left eyes (74 ± 25 s vs. 89 ± 27 s, p < 0.0001). When analyzing laterality and iris color, surgery was shortest in right eyes with light irides (68 ± 19 s) and longest in left eyes with dark irides (97 ± 31 s; p < 0.0001). Conclusions: SMILE surgery took significantly less time in patients with light irides and in the right eyes compared to dark irides and the left eyes. These findings suggest that patients’ iris color and laterality in relation to surgeon handedness may influence the ease of surgical lenticule extraction to a comparable extent.
- Open Access
- 11 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 7037
Hydrus® Microstent Combined with Cataract Surgery in Pseudoexfoliation Glaucoma Versus Primary Open Angle Glaucoma
Background/Objectives: Our objective was to compare clinical outcomes of the Hydrus® Microstent implantation combined with cataract surgery in eyes with pseudoexfoliation glaucoma (PXG) and primary open angle glaucoma (POAG). Methods: This retrospective, single-center comparative cohort study included eyes with POAG or PXG undergoing combined cataract surgery and Hydrus® Microstent implantation between June 2021 and December 2025 at the University Eye Hospital of the Ludwig Maximilian University in Munich, Germany. Clinical outcomes were evaluated until 8–14 months after surgery. Results: A total of 74 eyes were included, comprising 49 POAG eyes and 25 PXG eyes. After cataract surgery plus Hydrus® Microstent, IOP decreased significantly in both groups from baseline to the final 8–14-month follow-up (POAG: 17.6 ± 3.9 to 13.8 ± 2.3 mmHg, p < 0.0001; PXG: 19.2 ± 4.3 to 14.6 ± 2.7 mmHg, p < 0.0001). The magnitude of IOP reduction did not differ between groups (p = 0.410). Meanwhile, the number of IOP-lowering medications decreased significantly in both groups with no between-group difference (POAG: −1.20 medications; PXG group −1.09 medications, p = 0.724). Surgical success rates were comparable. Conclusions: Hydrus® Microstent implantation combined with cataract surgery showed comparable surgical outcomes in POAG and PXG eyes. Regardless of the more aggressive disease characteristics of PXG, no significant differences were observed between PXG and POAG eyes regarding IOP reduction, medication burden, BCVA, surgical success, complications or safety outcomes. These findings suggest that combined cataract surgery and Hydrus® Microstent implantation may be a useful treatment option in selected patients with PXG.
- 11 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 7037
Open AccessHydrus® Microstent Combined with Cataract Surgery in Pseudoexfoliation Glaucoma Versus Primary Open Angle Glaucoma
Background/Objectives: Our objective was to compare clinical outcomes of the Hydrus® Microstent implantation combined with cataract surgery in eyes with pseudoexfoliation glaucoma (PXG) and primary open angle glaucoma (POAG). Methods: This retrospective, single-center comparative cohort study included eyes with POAG or PXG undergoing combined cataract surgery and Hydrus® Microstent implantation between June 2021 and December 2025 at the University Eye Hospital of the Ludwig Maximilian University in Munich, Germany. Clinical outcomes were evaluated until 8–14 months after surgery. Results: A total of 74 eyes were included, comprising 49 POAG eyes and 25 PXG eyes. After cataract surgery plus Hydrus® Microstent, IOP decreased significantly in both groups from baseline to the final 8–14-month follow-up (POAG: 17.6 ± 3.9 to 13.8 ± 2.3 mmHg, p < 0.0001; PXG: 19.2 ± 4.3 to 14.6 ± 2.7 mmHg, p < 0.0001). The magnitude of IOP reduction did not differ between groups (p = 0.410). Meanwhile, the number of IOP-lowering medications decreased significantly in both groups with no between-group difference (POAG: −1.20 medications; PXG group −1.09 medications, p = 0.724). Surgical success rates were comparable. Conclusions: Hydrus® Microstent implantation combined with cataract surgery showed comparable surgical outcomes in POAG and PXG eyes. Regardless of the more aggressive disease characteristics of PXG, no significant differences were observed between PXG and POAG eyes regarding IOP reduction, medication burden, BCVA, surgical success, complications or safety outcomes. These findings suggest that combined cataract surgery and Hydrus® Microstent implantation may be a useful treatment option in selected patients with PXG.
- 27 July 2026
- Published by Wolters Kluwer Health in Retina
Correspondence
Was not provided for this article.
- 27 July 2026
- Published by Wolters Kluwer Health in Retina
Correspondence
Was not provided for this article.
- Open Access
Deferoxamine Modulates Corneal Endothelial Cell Biological Properties Associated with Increased VEGF Expression
Background and Objectives: The objective of this study is to evaluate whether deferoxamine modulates cell biological properties, such as proliferation and wound closure of porcine corneal endothelial cells (CECs) in vitro, and whether the treatment of CECs with deferoxamine results in an enhanced expression of vascular endothelial growth factor (VEGF). Materials and Methods: Corneal endothelial cells were extracted from porcine globes within 24 h postmortem. Immunohistochemistry for the endothelial Na+/K+-ATPase was performed to confirm the cells’ endothelial origin. To assess CEC viability and proliferation, a water-soluble tetrazolium salt (WST-1) and 5-bromo-2′-deoxyuridine (BrdU) assay were performed. Corneal endothelial wound closure was evaluated using a wound closure assay. VEGF mRNA expression was evaluated using real-time polymerase chain reaction (rt-PCR). Results: The extracted corneal endothelial cells showed a typical hexagonal morphology with Na+/K+-ATPase staining of the cell membrane. The treatment with 200 µM deferoxamine significantly increased CEC viability to 121 ± 24% compared to the control group (p = 0.0024). Corneal endothelial cell proliferation did not show any significant changes under the treatment with deferoxamine (p > 0.05). Both 100 µM and 200 µM deferoxamine led to a significantly smaller remaining wound area of 82.4 ± 6.7% and 78.7 ± 6.2% (p < 0.0001) in comparison to the control group after 24 h of treatment in the wound closure assay. Treatment with 200 µM deferoxamine significantly induced VEGF mRNA expression to 1.67- ± 0.57-fold from 1.00- ± 0.03-fold in the control group (p = 0.0006). Conclusions: Deferoxamine effectively enhances corneal endothelial cell viability and wound healing associated with an overexpression of VEGF. Thus, deferoxamine is a potent modulator of cell biological properties of corneal endothelial cells and maintains their integrity in vitro.
Open AccessDeferoxamine Modulates Corneal Endothelial Cell Biological Properties Associated with Increased VEGF Expression
Background and Objectives: The objective of this study is to evaluate whether deferoxamine modulates cell biological properties, such as proliferation and wound closure of porcine corneal endothelial cells (CECs) in vitro, and whether the treatment of CECs with deferoxamine results in an enhanced expression of vascular endothelial growth factor (VEGF). Materials and Methods: Corneal endothelial cells were extracted from porcine globes within 24 h postmortem. Immunohistochemistry for the endothelial Na+/K+-ATPase was performed to confirm the cells’ endothelial origin. To assess CEC viability and proliferation, a water-soluble tetrazolium salt (WST-1) and 5-bromo-2′-deoxyuridine (BrdU) assay were performed. Corneal endothelial wound closure was evaluated using a wound closure assay. VEGF mRNA expression was evaluated using real-time polymerase chain reaction (rt-PCR). Results: The extracted corneal endothelial cells showed a typical hexagonal morphology with Na+/K+-ATPase staining of the cell membrane. The treatment with 200 µM deferoxamine significantly increased CEC viability to 121 ± 24% compared to the control group (p = 0.0024). Corneal endothelial cell proliferation did not show any significant changes under the treatment with deferoxamine (p > 0.05). Both 100 µM and 200 µM deferoxamine led to a significantly smaller remaining wound area of 82.4 ± 6.7% and 78.7 ± 6.2% (p < 0.0001) in comparison to the control group after 24 h of treatment in the wound closure assay. Treatment with 200 µM deferoxamine significantly induced VEGF mRNA expression to 1.67- ± 0.57-fold from 1.00- ± 0.03-fold in the control group (p = 0.0006). Conclusions: Deferoxamine effectively enhances corneal endothelial cell viability and wound healing associated with an overexpression of VEGF. Thus, deferoxamine is a potent modulator of cell biological properties of corneal endothelial cells and maintains their integrity in vitro.
- Open Access
- 8 March 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (5) , 801
Quantitative Comparison of Two Novel Swept-Source Optical Coherence Tomography Angiography Devices
Background: Swept-source optical coherence tomography angiography (SS-OCTA) enables rapid assessment of retinal microvasculature. However, cross-platform comparability remains limited by device-specific acquisition and image quality characteristics. This study prospectively compared two novel SS-OCTA systems, DREAM (200 kHz) and BMizar (400 kHz). Methods: Fifty eyes from 25 healthy participants underwent 3 mm × 3 mm macular OCTA imaging with both devices in a single session. Images were analysed using OCTAVA to extract foveal avascular zone (FAZ) area, vessel area density (VAD), total vessel length (TVL), node counts, fractal dimension (FD), median vessel length (MVL) in SCP, and mean vessel diameter (MVD) in DCP. Image quality was assessed using FAZ-noise rate, contrast-to-noise ratio (CNR), and FAZ noise-floor standard deviation. Paired comparisons were performed using Wilcoxon signed-rank tests and Cliff’s delta. Results: BMizar acquisition time was shorter than DREAM for the evaluated 3 × 3 mm protocol (median 5.36 s vs. 9.93 s), reflecting differences in A-scan rate and protocol implementation; acquisition time is therefore reported descriptively. In the SCP, DREAM yielded lower VAD (41.9% vs. 48.8%) and fewer nodes (1547 vs. 1879) but exhibited markedly less background noise (noise-floor SD 4.1 vs. 57.9) and substantially higher CNR (16.7 vs. 0.82). DREAM also showed longer MVL (45 vs. 39 µm) and higher FD (1.98 vs. 1.97; δ = 0.90). In the DCP, DREAM demonstrated smaller FAZ areas (0.27 vs. 0.42 mm2), thinner MVD (14 vs. 25 µm), higher node counts (3144 vs. 2301), longer TVL (223.6 vs. 206.2 mm), and higher FD (1.98 vs. 1.97), whereas VAD was higher on BMizar (32.96% for DREAM vs. 49.93% for BMizar). FAZ-noise rates were consistently higher for BMizar in both plexuses. Conclusions: Both devices provide reliable SS-OCTA imaging, but with distinct strengths. DREAM delivers higher vascular continuity and more reliable FAZ and DCP quantification, whereas BMizar achieves faster acquisition at the cost of noise, inflating SCP density and distorting FAZ-based metrics. Awareness of these characteristics is essential to ensure the valid use of OCTA biomarkers in clinical and research applications.
- 8 March 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (5) , 801
Open AccessQuantitative Comparison of Two Novel Swept-Source Optical Coherence Tomography Angiography Devices
Background: Swept-source optical coherence tomography angiography (SS-OCTA) enables rapid assessment of retinal microvasculature. However, cross-platform comparability remains limited by device-specific acquisition and image quality characteristics. This study prospectively compared two novel SS-OCTA systems, DREAM (200 kHz) and BMizar (400 kHz). Methods: Fifty eyes from 25 healthy participants underwent 3 mm × 3 mm macular OCTA imaging with both devices in a single session. Images were analysed using OCTAVA to extract foveal avascular zone (FAZ) area, vessel area density (VAD), total vessel length (TVL), node counts, fractal dimension (FD), median vessel length (MVL) in SCP, and mean vessel diameter (MVD) in DCP. Image quality was assessed using FAZ-noise rate, contrast-to-noise ratio (CNR), and FAZ noise-floor standard deviation. Paired comparisons were performed using Wilcoxon signed-rank tests and Cliff’s delta. Results: BMizar acquisition time was shorter than DREAM for the evaluated 3 × 3 mm protocol (median 5.36 s vs. 9.93 s), reflecting differences in A-scan rate and protocol implementation; acquisition time is therefore reported descriptively. In the SCP, DREAM yielded lower VAD (41.9% vs. 48.8%) and fewer nodes (1547 vs. 1879) but exhibited markedly less background noise (noise-floor SD 4.1 vs. 57.9) and substantially higher CNR (16.7 vs. 0.82). DREAM also showed longer MVL (45 vs. 39 µm) and higher FD (1.98 vs. 1.97; δ = 0.90). In the DCP, DREAM demonstrated smaller FAZ areas (0.27 vs. 0.42 mm2), thinner MVD (14 vs. 25 µm), higher node counts (3144 vs. 2301), longer TVL (223.6 vs. 206.2 mm), and higher FD (1.98 vs. 1.97), whereas VAD was higher on BMizar (32.96% for DREAM vs. 49.93% for BMizar). FAZ-noise rates were consistently higher for BMizar in both plexuses. Conclusions: Both devices provide reliable SS-OCTA imaging, but with distinct strengths. DREAM delivers higher vascular continuity and more reliable FAZ and DCP quantification, whereas BMizar achieves faster acquisition at the cost of noise, inflating SCP density and distorting FAZ-based metrics. Awareness of these characteristics is essential to ensure the valid use of OCTA biomarkers in clinical and research applications.
- Open Access
- 9 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (4) , 1350
Mechanisms of Gas-Induced Posterior Vitreous Detachment: A Look Behind the Bubble Using Optical Coherence Tomography in Prone Position
Objectives: We aimed to visualize the interaction of intravitreal gas with the adjacent vitreomacular interface by using prone position (PP) SD-OCT and suggest possible mechanisms of action behind gas-induced posterior vitreous detachment (PVD) in pneumatic vitreolysis (PV). Methods: This was a descriptive–interpretative morphological study. Spectral domain OCT imaging in PP was carried out using a flexible scanning module (SD-OCT-Flex, Heidelberg Engineering) originally designed for bedside imaging. Routine imaging in sitting position was carried out using a regular SD-OCT-device (Heidelberg Engineering). Patients with symptomatic vitreomacular traction (VMT) scheduled for PV with perfluoropropane (C3F8, 0.3 mL) received both sitting and PP imaging immediately before and at regular follow-up visits during the first 3 post-procedural weeks, beginning 3 h after PV. Imaging was reviewed for positional changes of the gas bubble, posterior hyaloid membrane (PHM), VMT configuration, and retrohyaloidal fluid (RHF). Results: Three consecutive patients with VMT were included (age: 79, 80, 82 years). Before the procedure, no positional alterations were detected. After the intravitreal injection of gas, PP allowed for the precise discrimination of the PHM and the posterior border of the gas bubble. In contrast to regular SD-OCT in sitting position, PP imaging showed a flattened VMT by the gas bubble with consecutive displacement of RHF from the macular region to the midperiphery. Conclusions: This exploratory study describes PP imaging as a tool for the assessment of the morphologic dynamics between the posterior hyaloid membrane, retina, and gas bubble in pneumatic vitreolysis. PP in pneumatic vitreolysis causes the gas bubble to flatten the VMT and to push retrohyaloidal fluid to the midperiphery, possibly allowing for the release of persistent vitreoretinal adhesions and consequent PVD induction.
- 9 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (4) , 1350
Open AccessMechanisms of Gas-Induced Posterior Vitreous Detachment: A Look Behind the Bubble Using Optical Coherence Tomography in Prone Position
Objectives: We aimed to visualize the interaction of intravitreal gas with the adjacent vitreomacular interface by using prone position (PP) SD-OCT and suggest possible mechanisms of action behind gas-induced posterior vitreous detachment (PVD) in pneumatic vitreolysis (PV). Methods: This was a descriptive–interpretative morphological study. Spectral domain OCT imaging in PP was carried out using a flexible scanning module (SD-OCT-Flex, Heidelberg Engineering) originally designed for bedside imaging. Routine imaging in sitting position was carried out using a regular SD-OCT-device (Heidelberg Engineering). Patients with symptomatic vitreomacular traction (VMT) scheduled for PV with perfluoropropane (C3F8, 0.3 mL) received both sitting and PP imaging immediately before and at regular follow-up visits during the first 3 post-procedural weeks, beginning 3 h after PV. Imaging was reviewed for positional changes of the gas bubble, posterior hyaloid membrane (PHM), VMT configuration, and retrohyaloidal fluid (RHF). Results: Three consecutive patients with VMT were included (age: 79, 80, 82 years). Before the procedure, no positional alterations were detected. After the intravitreal injection of gas, PP allowed for the precise discrimination of the PHM and the posterior border of the gas bubble. In contrast to regular SD-OCT in sitting position, PP imaging showed a flattened VMT by the gas bubble with consecutive displacement of RHF from the macular region to the midperiphery. Conclusions: This exploratory study describes PP imaging as a tool for the assessment of the morphologic dynamics between the posterior hyaloid membrane, retina, and gas bubble in pneumatic vitreolysis. PP in pneumatic vitreolysis causes the gas bubble to flatten the VMT and to push retrohyaloidal fluid to the midperiphery, possibly allowing for the release of persistent vitreoretinal adhesions and consequent PVD induction.
- Open Access
- 17 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (24) , 8927
Comparison of ChatGPT-4o and DeepSeek R1 in the Management of Ophthalmological Emergencies—An Analysis of Ten Fictional Case Vignettes
Background: Generative artificial intelligence (AI) applications have gained increasing popularity in recent years and are used by an ever-increasing number of people on a day-to-day basis. While the performance of the earlier-generation generative AI ChatGPT-3.5 in the context of ophthalmologic emergencies has been previously assessed, the purpose of this study is to analyze the performance of the newer-generation generative AIs DeepSeek R1 (Hangzhou DeepSeek Artificial Intelligence Co., Ltd., Hangzhou, China) and ChatGPT-4o (OpenAI Inc., San Francisco, CA, USA) in the context of diagnosis, triage and prehospital management of ophthalmological emergencies. Methods: Ten previously published fictional case vignettes representing queries in the English language of patients experiencing acute ophthalmological symptoms were entered into the generative AIs DeepSeek R1 and ChatGPT-4o. The interaction with the generative AIs followed a previously described structured interaction path. In a random order, each case vignette was entered into separate chats five times, producing a total of 50 answers from each generative AI. Each answer was analyzed according to a previously published manual. Results: We observed better values for DeepSeek R1 compared to ChatGPT-4o in terms of treatment accuracy (60% compared to 50%), the share of answers containing wrong (46% compared to 60%) or conflicting information (30% compared to 40%), the share of answers that correctly captured the overall severity of symptoms (98% compared to 78%), as well as the share of potentially harmful answers (38% compared to 50%). Moreover, DeepSeek R1 more frequently provided a single diagnosis (20% compared to 16%) and specific treatment advice (42% compared to 20%) than ChatGPT-4o. Both generative AIs showed a diagnostic accuracy of 100%, i.e., whenever they provided a single diagnosis, this was indeed the correct diagnosis. In terms of triage accuracy, ChatGPT-4o performed slightly better than DeepSeek R1 (73% compared to 66%). In contrast to DeepSeek R1, which never directed questions back at the user, ChatGPT-4o always did. The direction of questions at the user enables dialogues with ChatGPT-4o that more closely resemble the actual taking of a patient’s history. However, DeepSeek R1 seems to perform better compared to ChatGPT-4o in terms of several important content-related metrics and has been shown to be more cost-effective in other studies. Conclusions: Both newer-generation generative AIs constitute remarkable milestones in the development of generative artificial intelligence. However, since potentially harmful recommendations were observed with both models, we currently do not recommend their use as sole source of information on ophthalmological emergencies for laypersons.
- 17 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (24) , 8927
Open AccessComparison of ChatGPT-4o and DeepSeek R1 in the Management of Ophthalmological Emergencies—An Analysis of Ten Fictional Case Vignettes
Background: Generative artificial intelligence (AI) applications have gained increasing popularity in recent years and are used by an ever-increasing number of people on a day-to-day basis. While the performance of the earlier-generation generative AI ChatGPT-3.5 in the context of ophthalmologic emergencies has been previously assessed, the purpose of this study is to analyze the performance of the newer-generation generative AIs DeepSeek R1 (Hangzhou DeepSeek Artificial Intelligence Co., Ltd., Hangzhou, China) and ChatGPT-4o (OpenAI Inc., San Francisco, CA, USA) in the context of diagnosis, triage and prehospital management of ophthalmological emergencies. Methods: Ten previously published fictional case vignettes representing queries in the English language of patients experiencing acute ophthalmological symptoms were entered into the generative AIs DeepSeek R1 and ChatGPT-4o. The interaction with the generative AIs followed a previously described structured interaction path. In a random order, each case vignette was entered into separate chats five times, producing a total of 50 answers from each generative AI. Each answer was analyzed according to a previously published manual. Results: We observed better values for DeepSeek R1 compared to ChatGPT-4o in terms of treatment accuracy (60% compared to 50%), the share of answers containing wrong (46% compared to 60%) or conflicting information (30% compared to 40%), the share of answers that correctly captured the overall severity of symptoms (98% compared to 78%), as well as the share of potentially harmful answers (38% compared to 50%). Moreover, DeepSeek R1 more frequently provided a single diagnosis (20% compared to 16%) and specific treatment advice (42% compared to 20%) than ChatGPT-4o. Both generative AIs showed a diagnostic accuracy of 100%, i.e., whenever they provided a single diagnosis, this was indeed the correct diagnosis. In terms of triage accuracy, ChatGPT-4o performed slightly better than DeepSeek R1 (73% compared to 66%). In contrast to DeepSeek R1, which never directed questions back at the user, ChatGPT-4o always did. The direction of questions at the user enables dialogues with ChatGPT-4o that more closely resemble the actual taking of a patient’s history. However, DeepSeek R1 seems to perform better compared to ChatGPT-4o in terms of several important content-related metrics and has been shown to be more cost-effective in other studies. Conclusions: Both newer-generation generative AIs constitute remarkable milestones in the development of generative artificial intelligence. However, since potentially harmful recommendations were observed with both models, we currently do not recommend their use as sole source of information on ophthalmological emergencies for laypersons.
- Open Access
High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent?
Purpose: To describe the indication spectrum for high-dose 8 mg aflibercept for neovascular age-related macular degeneration (nAMD) in a real-world cohort in a tertiary referral center. Methods: The database of the University Eye Hospital Munich, Ludwig Maximilians-University was screened for eyes with nAMD treated with 8 mg aflibercept. Demographic data, multimodal imaging and treatment parameters were recorded. Reasons for treatment with 8 mg aflibercept were analyzed. Results: Thirty-four consecutive eyes of 31 patients (mean age 78.6 ± 8.9 years) were identified. There were 22 women (70.1%) and 9 men (29.9%). In all eyes (100%), 8 mg Aflibercept was applied as switching therapy. Prior to switching, the mean anti-vascular endothelial growth factor (VEGF) treatment duration for nAMD was 3.9 ± 2.9 years, pretreatment amounted to a mean of 34.5 ± 26.3 injections, equaling 9.2 ± 2.4 injections/year, and the mean visual acuity (VA) was 0.4 ± 0.4 logMAR. The last treatment before switching was 2 mg aflibercept in 76%, faricimab in 18%, ranibizumab in 3% and bevacizumab in 3% of cases. Reasons for switching included (A) recalcitrant nAMD with persistent fluid despite q4w dosing (17 eyes, 50%), (B) the wish for interval extension (15 eyes, 44%) and (C) macular hemorrhage (2 eyes, 6%). In group B, two-thirds of eyes (10/15, 66.7%) were maintained at ≤q6w prior to switching. Conclusions: In this study, high-dose 8 mg aflibercept was exclusively used as a switch therapy. Most eyes (76%) switched were from pretreatment with 2 mg aflibercept. The main reasons for switching were recalcitrant nAMD with persistent fluid despite q4w dosing (50%) or the wish for treatment extension beyond 6 weeks (32%). In the future, these data will aid in the design of prospective real-world studies comparing the efficacy of high-dose 8 mg aflibercept with older generation treatment options, especially 2 mg aflibercept.
Open AccessHigh-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent?
Purpose: To describe the indication spectrum for high-dose 8 mg aflibercept for neovascular age-related macular degeneration (nAMD) in a real-world cohort in a tertiary referral center. Methods: The database of the University Eye Hospital Munich, Ludwig Maximilians-University was screened for eyes with nAMD treated with 8 mg aflibercept. Demographic data, multimodal imaging and treatment parameters were recorded. Reasons for treatment with 8 mg aflibercept were analyzed. Results: Thirty-four consecutive eyes of 31 patients (mean age 78.6 ± 8.9 years) were identified. There were 22 women (70.1%) and 9 men (29.9%). In all eyes (100%), 8 mg Aflibercept was applied as switching therapy. Prior to switching, the mean anti-vascular endothelial growth factor (VEGF) treatment duration for nAMD was 3.9 ± 2.9 years, pretreatment amounted to a mean of 34.5 ± 26.3 injections, equaling 9.2 ± 2.4 injections/year, and the mean visual acuity (VA) was 0.4 ± 0.4 logMAR. The last treatment before switching was 2 mg aflibercept in 76%, faricimab in 18%, ranibizumab in 3% and bevacizumab in 3% of cases. Reasons for switching included (A) recalcitrant nAMD with persistent fluid despite q4w dosing (17 eyes, 50%), (B) the wish for interval extension (15 eyes, 44%) and (C) macular hemorrhage (2 eyes, 6%). In group B, two-thirds of eyes (10/15, 66.7%) were maintained at ≤q6w prior to switching. Conclusions: In this study, high-dose 8 mg aflibercept was exclusively used as a switch therapy. Most eyes (76%) switched were from pretreatment with 2 mg aflibercept. The main reasons for switching were recalcitrant nAMD with persistent fluid despite q4w dosing (50%) or the wish for treatment extension beyond 6 weeks (32%). In the future, these data will aid in the design of prospective real-world studies comparing the efficacy of high-dose 8 mg aflibercept with older generation treatment options, especially 2 mg aflibercept.
- Open Access
- 13 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (20) , 7197
Extended Real-World Efficacy of Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: 9-Month Follow-Up Results
Background: Macular edema (ME) secondary to retinal vein occlusion (RVO) is a significant cause of vision impairment. Many patients show suboptimal responses to anti-vascular endothelial growth factor (anti-VEGF) monotherapy, prompting the exploration of alternative treatments. Faricimab is a bispecific antibody that targets VEGF-A and angiopoietin-2. We report 9-month real-world outcomes of switching to faricimab in therapy-resistant RVO-associated ME. Methods: In this retrospective study at a single tertiary center, patients with persistent or recurrent ME despite prior treatments (ranibizumab, aflibercept, or dexamethasone implant) were switched to faricimab. All eyes received a loading phase of four monthly faricimab injections, followed by a treat-and-extend regimen individualized per response. Key outcomes included best-corrected visual acuity (BCVA, logMAR), the central subfield thickness (CST, μm), and the intraretinal fluid (IRF) status on optical coherence tomography, assessed from the baseline (month 0, mo0) through the loading phase (mo1–mo3) and at month 9 (mo9). Results: Nineteen eyes (19 patients, mean age 64.8 years) were analyzed. The median BCVA improved from 0.20 to 0.00 logMAR by month 3 (p < 0.01) and was maintained at month 9. The median CST decreased from 325 μm at the baseline to 285 μm at month 3 (p < 0.01) and remained at 285 μm at month 9. IRF was present in 100% of eyes at the baseline, 26% at month 3, and 26% at month 9 (p < 0.01 for the baseline vs. month 9). Among eyes previously on anti-VEGF therapy (n = 14), the median treatment interval increased from 45.50 days at the baseline to 56.50 days at month 9 (p = 0.01; δ = 0.86). No intraocular inflammation or other adverse events were observed in this cohort over nine months. Conclusions: In this retrospective series, switching to faricimab was associated with improvements in vision and retinal anatomy that were maintained over 9 months; injection intervals were extended in a subset of eyes. These exploratory findings warrant confirmation in larger, controlled studies to define long-term effectiveness, safety, and dosing strategies.
- 13 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (20) , 7197
Open AccessExtended Real-World Efficacy of Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: 9-Month Follow-Up Results
Background: Macular edema (ME) secondary to retinal vein occlusion (RVO) is a significant cause of vision impairment. Many patients show suboptimal responses to anti-vascular endothelial growth factor (anti-VEGF) monotherapy, prompting the exploration of alternative treatments. Faricimab is a bispecific antibody that targets VEGF-A and angiopoietin-2. We report 9-month real-world outcomes of switching to faricimab in therapy-resistant RVO-associated ME. Methods: In this retrospective study at a single tertiary center, patients with persistent or recurrent ME despite prior treatments (ranibizumab, aflibercept, or dexamethasone implant) were switched to faricimab. All eyes received a loading phase of four monthly faricimab injections, followed by a treat-and-extend regimen individualized per response. Key outcomes included best-corrected visual acuity (BCVA, logMAR), the central subfield thickness (CST, μm), and the intraretinal fluid (IRF) status on optical coherence tomography, assessed from the baseline (month 0, mo0) through the loading phase (mo1–mo3) and at month 9 (mo9). Results: Nineteen eyes (19 patients, mean age 64.8 years) were analyzed. The median BCVA improved from 0.20 to 0.00 logMAR by month 3 (p < 0.01) and was maintained at month 9. The median CST decreased from 325 μm at the baseline to 285 μm at month 3 (p < 0.01) and remained at 285 μm at month 9. IRF was present in 100% of eyes at the baseline, 26% at month 3, and 26% at month 9 (p < 0.01 for the baseline vs. month 9). Among eyes previously on anti-VEGF therapy (n = 14), the median treatment interval increased from 45.50 days at the baseline to 56.50 days at month 9 (p = 0.01; δ = 0.86). No intraocular inflammation or other adverse events were observed in this cohort over nine months. Conclusions: In this retrospective series, switching to faricimab was associated with improvements in vision and retinal anatomy that were maintained over 9 months; injection intervals were extended in a subset of eyes. These exploratory findings warrant confirmation in larger, controlled studies to define long-term effectiveness, safety, and dosing strategies.
- Open Access
- 8 September 2025
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 276 (3) , 1137-1148
Clinical deep phenotyping of treatment response in schizophrenia (CDP-STAR): design and methodology of a prospective multimodal observational study
Schizophrenia spectrum disorders (SSDs) exhibit a marked heterogeneity in clinical course and treatment outcomes. Some individuals achieve remission and recovery, whereas others experience repeated relapses and progressive deterioration in psychosocial functioning. This variability underscores the unmet clinical need for prognostic biomarkers to predict treatment outcomes and guide personalized care. Deep phenotyping with multimodal data integration holds promise for understanding this complexity and delivering clinically relevant predictive models of treatment response in SSDs. To address this need, we initiated the Clinical Deep Phenotyping of Treatment Response in Schizophrenia (CDP-STAR) study, a prospective, naturalistic, longitudinal observational study integrating comprehensive multimodal assessments. These include clinical phenotyping, magnetic resonance imaging (MRI), electroencephalography (EEG), retinal imaging, and extensive sampling of blood and cerebrospinal fluid (CSF) for multi-omics profiling. The study aims to externally validate promising biomarker candidates and elucidate the pathophysiological mechanisms underlying treatment outcomes. This innovative deep phenotyping framework integrates data across multiple critical domains, enabling external validation of potential biomarkers and the discovery of novel ones. Ultimately, the CDP-STAR study aims to yield mechanistic insights that advance precision psychiatry and inform clinical decision-making in SSDs.
- 8 September 2025
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 276 (3) , 1137-1148
Open AccessClinical deep phenotyping of treatment response in schizophrenia (CDP-STAR): design and methodology of a prospective multimodal observational study
Schizophrenia spectrum disorders (SSDs) exhibit a marked heterogeneity in clinical course and treatment outcomes. Some individuals achieve remission and recovery, whereas others experience repeated relapses and progressive deterioration in psychosocial functioning. This variability underscores the unmet clinical need for prognostic biomarkers to predict treatment outcomes and guide personalized care. Deep phenotyping with multimodal data integration holds promise for understanding this complexity and delivering clinically relevant predictive models of treatment response in SSDs. To address this need, we initiated the Clinical Deep Phenotyping of Treatment Response in Schizophrenia (CDP-STAR) study, a prospective, naturalistic, longitudinal observational study integrating comprehensive multimodal assessments. These include clinical phenotyping, magnetic resonance imaging (MRI), electroencephalography (EEG), retinal imaging, and extensive sampling of blood and cerebrospinal fluid (CSF) for multi-omics profiling. The study aims to externally validate promising biomarker candidates and elucidate the pathophysiological mechanisms underlying treatment outcomes. This innovative deep phenotyping framework integrates data across multiple critical domains, enabling external validation of potential biomarkers and the discovery of novel ones. Ultimately, the CDP-STAR study aims to yield mechanistic insights that advance precision psychiatry and inform clinical decision-making in SSDs.